Accuray, Inc. (ARAY) Gets FDA Clearance to Market Unique Lung Cancer Treatment

QualityStocks would like to highlight Accuray Incorporated (NASDAQ: ARAY), based in Sunnyvale, Calif., a global leader in the field of radiosurgery. The company is dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas.

In the company’s news yesterday,

Accuray Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market Lung Optimized Treatment, a new component of the company’s CyberKnife® System.

The CyberKnife system is designed to assist physicians in delivering radiosurgery treatments to patients with lung cancer. To date, the system has been used to treat more than 100,000 patients worldwide.

Lung Optimized Treatment is a non-invasive option to safely treat lung tumors, regardless of tumor location, even those close to such critical structures. Treating tumors in near proximity to vital anatomical structures can be difficult, but Accuray’s technology offers multiple and reduced-risk treatment options.

“Lung Optimized Treatment is a new tool we developed to meet the clinical demand for more flexibility in treating lung cancer patients with radiosurgery and the desire to move away from reliance on fiducial markers,” Chris A. Raanes, senior vice president and chief operating officer for Accuray stated in the press release. “This new technology enables treatments throughout the lung without a single incision, all while safeguarding healthy tissue and structures around the tumor to ensure they are not damaged by radiation.”

Accuray’s CyberKnife Robotic Radiosurgery System is a one-of-its-kind system that uses continual image guidance technology and computer controlled robotic mobility to track, detect and correct tumor and patient movement in real-time throughout the treatment. This enables the delivery of high-dose radiation with ultimate precision, minimizing damage to surrounding healthy tissue, and eliminating the need for head or body stabilization.

The company highlights the importance of innovative technologies in this area of cancer treatement.

“With the FDA 510(k) clearance of Lung Optimized Treatment, we’ve taken the CyberKnife technology to new heights and enabled care for an expanded group of patients,” Euan S. Thomson, Ph.D., president and CEO of Accuray stated. “This is yet another step in our efforts to ensure physicians have access to the treatment choices necessary for their patient, based on the patient’s specific needs. To this end, Accuray continues to investigate ways to improve patient care across various indications.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.